Immunome, Inc. (IMNM)
15.69
-0.92
(-5.54%)
USD |
NASDAQ |
Nov 20, 16:00
15.70
0.00 (0.00%)
After-Hours: 20:00
Immunome Enterprise Value : 1.333B for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 1.333B |
| November 19, 2026 | 1.437B |
| November 18, 2026 | 1.457B |
| November 17, 2026 | 1.502B |
| November 16, 2026 | 1.551B |
| November 13, 2026 | 1.683B |
| November 12, 2026 | 1.675B |
| November 11, 2026 | 1.717B |
| November 10, 2026 | 1.669B |
| November 09, 2026 | 1.750B |
| November 06, 2026 | 1.676B |
| November 05, 2026 | 1.585B |
| November 04, 2026 | 1.768B |
| November 03, 2026 | 1.858B |
| November 02, 2026 | 1.776B |
| October 30, 2026 | 1.619B |
| October 29, 2026 | 1.628B |
| October 28, 2026 | 1.682B |
| October 27, 2026 | 1.683B |
| October 26, 2026 | 1.583B |
| October 23, 2026 | 1.594B |
| October 22, 2026 | 1.625B |
| October 21, 2026 | 1.595B |
| October 20, 2026 | 1.586B |
| October 19, 2026 | 1.456B |
| Date | Value |
|---|---|
| October 16, 2026 | 1.422B |
| October 15, 2026 | 1.527B |
| October 14, 2026 | 1.505B |
| October 13, 2026 | 1.548B |
| October 12, 2026 | 1.726B |
| October 09, 2026 | 1.772B |
| October 08, 2026 | 1.744B |
| October 07, 2026 | 1.720B |
| October 06, 2026 | 1.744B |
| October 05, 2026 | 1.956B |
| October 02, 2026 | 1.925B |
| October 01, 2026 | 1.924B |
| September 30, 2026 | 1.994B |
| September 29, 2026 | 1.964B |
| September 28, 2026 | 1.941B |
| September 25, 2026 | 1.910B |
| September 24, 2026 | 2.015B |
| September 23, 2026 | 2.231B |
| September 22, 2026 | 2.402B |
| September 21, 2026 | 2.325B |
| September 18, 2026 | 2.200B |
| September 17, 2026 | 2.196B |
| September 16, 2026 | 2.142B |
| September 15, 2026 | 2.198B |
| September 14, 2026 | 2.266B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 32.42B |
| Erasca, Inc. | 4.166B |
| Oncolytics Biotech, Inc. | 44.27M |
| Sangamo Therapeutics, Inc. | 35.66M |
| Sarepta Therapeutics, Inc. | 1.604B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -85.78M |
| Total Expenses (Quarterly) | 85.78M |
| EPS Diluted (Quarterly) | -0.7554 |
| Earnings Yield | -16.75% |
| Normalized Earnings Yield | -16.27 |